Lenire Included in U.S. Clinical Practice Guidelines for Tinnitus
Lenire, a bimodal neuromodulation device, has been included as a treatment option in the American Academy of Otolaryngology – Head and Neck Surgery Foundation's clinical practice guidelines for tinnitus. This is the first new treatment recommendation added since the guidelines' inception.
The American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNS) has incorporated Lenire, a bimodal neuromodulation device, into its clinical practice guidelines for the management of tinnitus. This marks the first novel treatment recommendation added to the academy's tinnitus guidelines since their initial establishment.
Lenire is designed to treat tinnitus by stimulating the tongue and the skin on the neck, aiming to provide relief from the condition's symptoms. The device is intended for use under the supervision of a healthcare professional.
The inclusion follows a review of available clinical evidence by the AAO-HNS, which provides guidance to healthcare providers in the United States. Tinnitus affects millions worldwide and can significantly impact quality of life, often leading to anxiety and sleep disturbances.
This recognition by a leading professional body is expected to increase awareness of Lenire as a therapeutic option for tinnitus patients. The guidelines aim to ensure patients receive evidence-based care.